<DOC>
	<DOCNO>NCT00657774</DOCNO>
	<brief_summary>The medication use study individually approve Food Drug Administration ( FDA ) . The medication investigation combination two medication one inhaler . The purpose study determine medication affect amount , , cortisol produce adrenal gland .</brief_summary>
	<brief_title>A Phase I Study Asthma Patients Evaluating Effect Doses FlutiForm™ Amount , Any , Cortisol Produced Adrenal Glands</brief_title>
	<detailed_description>This Phase-1 randomize , double-blind , placebo- active-controlled , parallel group 6 week study evaluate effect HPA axis treatment SKP FlutiForm 250/10 mg HFA pMDI twice daily administer 6 week , FlutiForm 100/10 mg HFA pMDI twice daily administer 6 week 10 mg prednisone administer 7 day compare placebo . All subject undergo Screening Visit determine eligibility study train pMDI use . Eligible subject meet follow criterion : least 6 month history asthma , demonstrate FEV1 least ≥ 60 % predict normal value Screening Baseline visit , stable asthma without use inhale steroid past month oral parenteral corticosteroid past three month . All subject admit study site morning Study Day -1 begin 24-hour urine collection undergo Baseline trough PK sample . On morning Study Day 1 , subject randomize one four treatment group : SKP FlutiForm 250/10 mg twice daily + placebo capsule six week , SKP FlutiForm 100/10 mg twice daily + placebo capsule six week , Placebo inhaler + placebo capsule six week Placebo inhaler six week + placebo capsule 5 week follow one week 10 mg prednisone QD . After first dose , subject discharge study site continue dose home 6 week . Subjects require record compliance twice daily inhaler dose daily oral medication dose diary . Subjects also record predose morning even Peak Expiratory Flow Rate ( PEFR ) diary . Clinic visit occur Study Days 7 , 14 35 safety assessment ( AEs vital sign ) make , trough PK sample obtain pMDI training continue . Also , subject return study site morning Study Days 40 41 observe dose prednisone placebo . Subjects readmitted study site morning Study Day 42 trough PK sampling , observe dose prednisone placebo begin 24-hour urine collection . A safety follow-up phone call occur 7 day later .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Age 1865 Screening Visit ; History asthma least 6 month prior Screening Visit Well control asthma rescue short act beta agonist ( albuterol ) stable dos medication least 4 week prior Screening Visit Female subject pregnant lactate Otherwise healthy determine Investigator . Lifethreatening asthma within past year visit emergency room asthma past 3 month prior Screening Visit ; Significant , nonreversible pulmonary disease ( e.g . chronic obstructive pulmonary disease , cystic fibrosis bronchiectasis ) Use steroid medication , topical inhale steroid within 4 week systemic ( oral injectable ) steroid within 3 month dose An upper low respiratory tract infection within last 4 week pior Screening Visit acute illness infection within 6 week prior dose Any significant disease major disorder may jeopardize subject safety History tabacco use within 6 month prior dose and/or smoke history &gt; 10 packyears Female subject hormone replacement therapy use birth control involve hormone past 6 month Additional inclusion exclusion criterion evaluate investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Mild Moderate</keyword>
</DOC>